[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nociplastic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nociplastic-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,78,103,137,160,190,224,260],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645231","emotional-allodynia-questionnaire-aeq-in-fibromyalgia-pearl-100645231",false,"NCT07677631","Emotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL)","Pain, Emotional Allodynia, and Relational Load (PEARL): A Multicenter Validation Study of the Emotional Allodynia Questionnaire in Fibromyalgia","PEARL","CASES (fibromyalgia)\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Clinical diagnosis of fibromyalgia confirmed according to the 2016 revision of the ACR criteria\n* Chronic non-cancer pain for at least 3 months\n* Ability to understand and independently complete self-report questionnaires in Italian\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Active oncological disease or cancer-related pain\n* Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder (assessed by clinical history)\n* Severe cognitive impairment precluding questionnaire completion\n* Inability to understand or complete questionnaires in Italian\n\nCONTROLS (non-fibromyalgia chronic pain)\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Chronic non-cancer pain for at least 3 months with a defined nociceptive or neuropathic generator (e.g., radiologically or surgically documented degenerative, structural, or post-surgical musculoskeletal pain, or neuropathic pain with an identifiable neurological lesion or disease)\n* Not meeting the 2016 ACR criteria for fibromyalgia\n* Ability to understand and independently complete self-report questionnaires in Italian\n* Willingness to provide written informed consent\n\nExclusion Criteria (parallel to cases):\n\n* Diagnosis of fibromyalgia or another recognized nociplastic primary pain condition (e.g., primary chronic widespread pain)\n* Active oncological disease or cancer-related pain\n* Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder\n* Severe cognitive impairment precluding questionnaire completion\n* Inability to understand or complete questionnaires in Italian\n\nNote: ongoing pharmacological treatment for pain or mental health is not an exclusion criterion in either group; Major Depressive Disorder and Panic Disorder are recorded at baseline and used in covariate-adjusted and stratified analyses.","ALL","18 Years",{"count":20,"type":21},423,"ESTIMATED","OBSERVATIONAL","The Emotional Allodynia Questionnaire (AEQ) is an 11-item self-report instrument that measures disproportionate emotional reactivity to low-intensity interpersonal cues(perceived unresponsiveness, exclusion, loss of reciprocity), a pattern termed emotional allodynia. It was preliminarily validated in a single-center fibromyalgia sample. PEARL (validation phase) is a multicenter, prospective, observational psychometric validation study that (1) replicates the internal structure and convergent validity of the AEQ in an independent fibromyalgia sample, (2) tests its known-groups (discriminative) accuracy in separating fibromyalgia from non-fibromyalgia chronic pain of defined nociceptive or neuropathic origin, expressed as the area under the ROC curve (AUC), and (3) assesses test-retest reliability. There is no intervention.",[25,26,27],"Fibromyalgia","Chronic Pain","Nociplastic Pain",[29,25,30,31,32,33],"Emotional Allodynia Questionnaire","Nociplastic pain","Psychometric validation","Central sensitization","Emotion regulation","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2025-09-10",{"date":42,"type":21},"2027-08",{"name":44,"class":45},"University of Bari","OTHER",5,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100641680","evolution-of-different-sensitivity-levels-in-patients-with-chronic-neuropathic-pain-in-the-pelvi-perineal-region-after-treatment-with-high-concentration-capsaicin-patches-100641680","NCT07660510","Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches","CAPSASENS","Inclusion Criteria:\n\n* Men or women ≥ 18 years old.\n* Patients suffering from chronic pelvi-perineal neuralgia (\\>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).\n* Patients who have signed the informed consent form for the study at the inclusion visit.\n* Women must meet one of the following criteria at the time of inclusion:\n* Use adequate contraceptive measures;\n* or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);\n* or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;\n* or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship, or legal protection.\n* Pregnant or breastfeeding women.\n* Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components.\n* Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).\n* Patients not affiliated with the French Social Security system.\n* Patients with insufficient cooperation and\u002For understanding to strictly comply with the protocol requirements.\n* Patients who have taken analgesics within the 12 hours prior to measurements.",{"count":55,"type":21},30,"INTERVENTIONAL",[58],"NA","The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.",[61,27],"Neuropathic Pain",[63,64,65,66],"Sensitization","8% capsaicin patch","Quantitative Sensory Testing","Temporal Summation","NOT_YET_RECRUITING","2026-06-15",{"date":70,"type":38},"2026-06-22",{"date":72,"type":21},"2026-09-01",{"date":74,"type":21},"2028-03-01",{"name":76,"class":45},"Nantes University Hospital",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":77},"100625495","vestibular-innovation-in-pain-2-100625495","NCT07423377","Vestibular Innovation in Pain 2","Vestibular Innovation in Pain: A Randomized Controlled Trial","VIPR","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Age equal to or \\>18 years old\n* Stated interest in and willingness to receive VCS and to complete the online patient reported outcomes before and after the procedure.\n* Owns or has access to a smart phone or computer to complete outcome measures\n* Fluency in English\n* Diagnosis of Fibromyalgia (FM)\n\n  * Diagnosis by American College of Rheumatology 2016 questionnaire\n  * Pain score 4\u002F10 or more and less than 10\u002F10 on the numeric rating scale at the time of inclusion.\n\nExclusion Criteria:\n\n* History of tympanic membrane injury, rupture, or surgery a. Including tympanostomy, or \"ear tubes,\" and\u002For cochlear implant.\n* Right ear infection within the last 3 months, or current right ear pain.\n* Current pregnancy\n* Bipolar Disorder\n* History of seizures (including non-epileptiform seizures)\n* History of syncope within the last 3 months. a. Not including presyncope or in setting of known medical illness (i.e., heatstroke)\n* Inability to lay supine for 15 minutes\n* Receiving disability benefits for fibromyalgia or involved in litigation related to fibromyalgia.\n* Clinically significant medical, psychological, or behavioral conditions that, in the opinion of the investigator, would compromise participation in the study.\n* History of or current Meniere's Disease\n* History of myocardial infarction (MI), stroke or TIA, or coronary artery bypass graft (CABG) in the last 3 months\n* History of hospitalization for severe hypertension\n* History of vestibular schwannoma or meningioma resection.\n* Patients taking opioid therapy (not including tramadol).",{"count":87,"type":21},56,[58],"Fibromyalgia is the most common centralized pain disorder, affecting up to 3% of the population. Current treatments are incompletely effective, often poorly tolerated, and costly: there remains an urgent need for novel, effective, and well-tolerated therapy. Preliminary data suggests that vestibulocortical stimulation (VCS), or irrigating the external ear canal with temperate water, could rapidly improve pain and quality of life in this cohort. The VIPR trial will assess the efficacy of a single session of VCS - a safe \\& cost-effective bedside technique using a plastic syringe and temperate water - relative to sham in treating pain \\& improving quality of life using validated patient-reported outcomes.",[25,27],[92,93],"pain","quality of life","2026-06-05",{"date":96,"type":38},"2026-06-08",{"date":98,"type":38},"2026-03-19",{"date":100,"type":21},"2027-07-31",{"name":102,"class":45},"Icahn School of Medicine at Mount Sinai",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":56,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":77},"100630864","usg-guided-shoulder-injections-in-frozen-shoulder-100630864","NCT07493213","USG-Guided Shoulder Injections in Frozen Shoulder","Effectiveness of USG-Guided Shoulder Injections as an Adjunct to a Home Exercise Program in the Conservative Management of Painful Frozen Shoulder and Its Association With Pain Phenotypes","Inclusion Criteria:\n\nAge between 18 and 75 years and willingness to participate in the study\n\nPresence of shoulder pain lasting at least 3 months and a diagnosis of primary frozen shoulder\n\nPain intensity ≥ 4\u002F10 on the Visual Analog Scale (VAS), resistant to medical treatment\u002Fanalgesics\n\nRestriction of ≥30 degrees in at least two planes of shoulder motion (flexion, abduction, or external rotation)\n\n\\-\n\nExclusion Criteria:\n\n* History of shoulder trauma\n\nPresence of neurological conditions such as stroke, brachial plexus injury, Parkinson's disease, or cervical spine pathology with or without radiculopathy\n\nHistory of shoulder surgery, shoulder malignancy or tumor, or prior shoulder manipulation\n\nPresence of shoulder arthritis, rotator cuff tear, other shoulder injuries, or thoracic outlet syndrome\n\nSystemic diseases affecting the shoulder, severe degeneration or trauma (e.g., osteoarthritis, rheumatoid arthritis, labral or articular cartilage injuries), or inflammatory rheumatic diseases\n\nSteroid injection to the affected extremity within the last 3 months, use of oral steroids or NSAIDs, or ongoing surgical\u002Finterventional treatment\n\nPregnancy or lactation\n\nUncontrolled diabetes, heart failure, or uncontrolled systemic diseases (e.g., liver failure, chronic kidney disease, significant endocrine disorders)\n\nCommunication problems or severe psychiatric disorders","75 Years",{"count":112,"type":21},68,[58],"Frozen shoulder (adhesive capsulitis) is characterized by pain and a progressive restriction of both active and passive shoulder range of motion, significantly impairing daily activities and quality of life. This study aims to evaluate the effectiveness of USG-guided shoulder injections, when added to a home-based exercise program, in the conservative management of patients with chronic, painful frozen shoulder.\n\nIn this prospective randomized study, patients diagnosed with painful frozen shoulder will be included. In addition to a standardized home-based exercise program, patients will receive either USG-guided suprascapular nerve block alone or a combination of suprascapular nerve block and subacromial injection. The effects of these approaches on clinical outcomes will be assessed over a 20-week follow-up period.\n\nPrimary outcome measures include pain intensity assessed by the Visual Analog Scale (VAS), functional status evaluated by the Shoulder Pain and Disability Index (SPADI), and shoulder range of motion. Secondary outcomes include depression level (Beck Depression Inventory), sleep quality, pain phenotype (nociplastic, neuropathic, or nociceptive), hand grip strength, ultrasonographic findings ( (coracohumeral ligament thickness, subacromial bursa thickness) , and patient satisfaction (subjective impression of improvement).\n\nThe results of this study are expected to provide evidence on the comparative effectiveness and additional benefits of different shoulder injection approaches when combined with home-based exercise therapy in patients with chronic frozen shoulder.",[116,117,118,27,61],"Frozen Shoulder","Adhesive Capsulitis","Shoulder Pain",[116,117,120,121,118,122,123,124,125,126],"Shoulder Injection","Home Exercise Program","Range of Motion","SPADI","Ultrasound-Guided Injection","pain phenotypes","exercises","2026-05-11",{"date":129,"type":38},"2026-05-14",{"date":131,"type":38},"2026-04-01",{"date":133,"type":21},"2027-06-30",{"name":135,"class":136},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":144,"targetDuration":4,"studyType":56,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":77},"100630865","efficacy-of-chemically-distinct-nonsteroidal-anti-inflammatory-drugs-nsaids-and-pain-phenotypes-in-adhesive-capsulitis-100630865","NCT07493226","Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis","Comparative Efficacy of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) With Distinct Chemical Structures in Shoulder Adhesive Capsulitis and the Role of Pain Phenotypes","Inclusion Criteria:\n\n1. Being between 18-75 years of age\n2. Having shoulder pain that has lasted for at least one month and being diagnosed with primary frozen shoulder\n3. Having a VAS pain level ≥ 4\u002F10\n4. Having ≥30 degrees of range of motion restriction in at least two planes (flexion, abduction, or external rotation)\n5. Not having any exclusion criteria and agreeing to participate in the study voluntarily\n\nExclusion Criteria:\n\n1. Patients with a history of shoulder trauma, those with musculoskeletal disorders characterized by pain and loss of function in the affected extremity (such as lateral epicondylitis, flexor tendon injury, de Quervein's tenosynovitis)\n2. Presence of neurological involvement such as stroke, brachial plexus injury, Parkinson's disease, and cervical spine injury with or without radiculopathy\n3. History of shoulder surgery, malignancy or tumor in the shoulder, those who have undergone shoulder manipulation\n4. Presence of shoulder arthritis, rotator cuff tear or other shoulder injuries, thoracic outlet syndrome\n5. Systemic disease affecting the shoulder region, severe degeneration or trauma (e.g., osteoarthritis, rheumatoid arthritis, history of labrum or articular cartilage injuries), inflammatory rheumatic diseases\n6. Those who have received steroid injections into the affected extremity within the last 3 months, those using oral steroids or NSAIDs, those receiving any surgical or interventional treatment, or Planned individuals:\n7. Those who are pregnant or lactating\n8. Those with uncontrolled diabetes, heart failure, uncontrolled systemic disease (liver disease, chronic kidney failure, significant endocrine disorders, etc.)\n9. Those with communication problems, severe psychiatric disorders\n10. Those allergic to NSAIDs or with any contraindications\n11. Those with bleeding, coagulation disorders, stomach ulcers, or symptomatic gastritis",{"count":145,"type":21},120,[58],"Patients aged 18-75 years who present to a tertiary rehabilitation hospital with shoulder pain and restricted range of motion, and who consent to participate, will be included in the study. Eligibility will be determined based on predefined inclusion and exclusion criteria.\n\nEligible patients will be randomly assigned to receive one of several nonsteroidal anti-inflammatory drugs (NSAIDs) with differing chemical properties (e.g., diclofenac, meloxicam, or indomethacin), in combination with a home-based exercise program for shoulder adhesive capsulitis. Patients' sociodemographic data, as well as detailed clinical and examination findings and baseline outcomes, will be recorded. Patients will be informed about their condition, and modifications to activities of daily living will be recommended.Patients' pain phenotypes (nociceptive, neuropathic, nociplastic) will be categorized based on clinical history and questionnaires, and it will be determined which pain types derive greater benefit from NSAIDs.\n\nFollow-up assessments will be conducted at the end of the first and second weeks. At the first-week follow-up, pain intensity will be evaluated using the Visual Analog Scale (VAS). If the treatment is deemed effective (defined as a ≥3-point reduction or ≥50% decrease in VAS), the same NSAID will be continued for an additional week; otherwise, it will be switched to an alternative NSAID with a different biochemical profile (group). The outcomes assessments will be performed by a blinded evaluator to minimize bias.",[116,117,118,149,27,61],"NSAID (Non-Steroidal Anti-Inflammatory Drug)",[151,152,153,125,126,154],"frozen shoulder","adhesive capsulitis","shoulder pain","Nonsteroidal Anti-Inflammatory Drugs",{"date":129,"type":38},{"date":131,"type":38},{"date":158,"type":21},"2027-03-30",{"name":135,"class":136},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":56,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":77},"100609184","efficacy-of-home-delivered-transcranial-direct-electrical-stimulation-or-chronic-pain-100609184","NCT07211256","Efficacy of Home-delivered Transcranial Direct Electrical Stimulation or Chronic Pain","Efficacy of Home-delivered Transcranial Direct Current Stimulation (tDCS) of the Motor Cortex in Patients With Chronic Pain Transiently Relieved by Motor Cortex rTMS : a Pragmatic Randomized Double Blind Sham Controlled Trial","Homestim-DC","Inclusion Criteria:\n\nChronic pain for at least 6 months Pain intensity ≥ 4\u002F10 on 0-10 NRS Pain present every day or nearly every day Neuropathic pain (DN4 score ≥ 4\u002F10) or nociplastic pain (Kosek et al Pain 2021) Patients previously treated with rTMS of the motor cortex in routine in our pain center but with only transient efficacy (ie, efficacy for less than one month, defined as pain intensity improved by at least 30 %) Affilitated to social security\n\nExclusion Criteria:\n\nContraindications to tDCS as stated in the manufacturer brochure (ie, implantable device , severe cognitive disorders, epilepsia, skin problems where will placed the electrodes, arterial or venous thrombosis, thrombophlebitis, metallic intracranial implant, cranioth-omy, incracranial aneuvrysm, cerebral tumor, severel sleep disorders such as narcolepsia) Conciomitant treatment which might increase the risk of epilepsia such as high doses opioids (≥ 140 mg morphine equivalent) or high. doses tricyclic antidepressants (≥ 150 mg per day) Pregnancy or lactation Age below 18 or \\> 80 years Pending litigation related to pain Pain more severe than neuropathic or nociplastic pain requiring treatment Severe disease such as cancer Severe psychiatric condition (psychosis) Impossible to be followed for up to 3 months Participation in a recent protocol (less than 3 months) Psychoactive drug abuse","80 Years",{"count":170,"type":21},70,[58],"This clinical investigation aims to evaluate the efficacy and safety of a home-based device providing electrical stimulation of the brain named transcranial direct current stimulation (tDCS ) , in patients with chronic pain who have been transiently relieved by repetitive transcranial magnetic stimulation delivered at hospital (less than one month benefit). The general objective is to show that these patients may best benefit from home based tDCS while rTMS performed in hospital has only limited and transient efficacy. Each participant will be randomized into one of two arms to receive during 3 months either active tDCS or sham tDCS. Neither the investigator nor the patient will be aware of the treatment. The efficacy will be assessed on pain intensity (primary outcome at 3 months) and several secondary outcomes (qualify of life, pain symptoms , global impression of change, pain relief, sleep, anxiety, depression) every month for up to 3 months. Safety will be assessed at each follow up visit for up to 3 months. The participants will be asked to self stimulate themselves with the device 5 days per week for about 20 minutes.",[61,27],[175,176,177,178,179,180],"randomized","neuropathic pain","nociplastic pain","placebo controlled","tDCS","home-delivered","2025-09-29",{"date":183,"type":38},"2025-10-07",{"date":185,"type":38},"2025-01-09",{"date":187,"type":21},"2028-02",{"name":189,"class":45},"Hospital Ambroise Paré Paris",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":56,"phases":201,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":77},"100591506","internet-delivered-psychological-treatments-for-chronic-pain-in-adolescents-act-and-pain-education-100591506","NCT06981312","Internet-Delivered Psychological Treatments for Chronic Pain in Adolescents: ACT and Pain Education.","Internet-Delivered Acceptance and Commitment Therapy for Chronic Pain in Adolescents: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adolescents aged 13-19 years with chronic pain (duration ≥ 3 months).\n* Have undergone a medical examination regarding their pain condition.\n* Are not using pain-relieving medication, or have been stable on such medication for at least 2 months, with no planned medication changes.\n* Have not undergone ACT or CBT treatment in the past six months.\n* Can read and write in Swedish without difficulty.\n* Have access to a smartphone\u002Fcomputer with an internet connection and e-ID.\n* Have at least one parent or guardian who is willing and able to participate in parallel parent support treatment.\n\nExclusion Criteria:\n\n* Insufficient understanding of Swedish to complete study-related tasks.\n* Adolescents currently undergoing ACT or CBT treatment.\n* Adolescents who are using pain-relieving medication or have unstable medication regimes.\n* Adolescents without access to a smartphone\u002Fcomputer or e-ID.","13 Years","19 Years",{"count":200,"type":21},150,[58],"One in four children in Sweden experiences chronic pain. For many, the pain is temporary, but for about 5% it significantly affects daily life, leading to sleep problems, school absence, and reduced physical activity. Youth with chronic pain report lower life satisfaction and overall health compared to their peers. In most cases, there is no underlying disease or injury, suggesting that chronic pain is a condition in itself, driven by dysregulation in the pain system and influenced by biological, psychological, and social factors.\n\nNational guidelines in Sweden recommend cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) for children and adolescents with chronic pain and substantial functional limitations. However, more high-quality randomized controlled trials (RCTs) are needed to strengthen the evidence base for these treatments.\n\nThe investigators' clinic has developed and evaluated ACT-based treatments for pediatric chronic pain over the past two decades. The protocol has now been adapted into an internet-delivered version to increase accessibility. In a preliminary feasibility study, the investigators observed promising effects on pain interference, though some usability issues have since been addressed.\n\nThe treatment is grounded in the fear-avoidance model, which explains how avoidance of pain-related activities can worsen disability over time. In ACT, such avoidance is seen as driven by unwanted thoughts, emotions, and bodily sensations. The aim of treatment is to help young people relate more flexibly to pain and fear and to move toward personally meaningful goals - a skill referred to as psychological flexibility. Exposure is a core component of ACT, encouraging patients to engage with avoided thoughts, feelings, and activities in order to reduce avoidance and improve functioning.\n\nIn addition to treating the young person, the study also targets parental behaviors. Parents often respond to their child's pain by increasing protection and monitoring, which is natural but can sometimes contribute to further avoidance and reduced independence in the child. ACT-based parent support is designed to help caregivers support their child more effectively.\n\nIn this randomized trial, internet-delivered ACT will be compared to two control conditions: (1) an active comparator involving online pain education, and (2) a passive control group on a wait list. The pain education intervention is based on Pain Science Education (PSE), which aims to shift how individuals understand their pain - from seeing it as a sign of injury to recognizing it as a false alarm in the nervous system. PSE has shown promising effects in adults, but research in youth is still limited, and no RCTs have yet been published.\n\nThe study responds to the need for well-designed digital interventions that reach more young people, evaluate treatment components more clearly, and include comparison groups that also receive digital interventions. The goal of the study is to further improve treatment effects by (1) emphasizing exposure strategies to reduce avoidance, (2) expanding pain education to enhance treatment understanding, and (3) refining parent support to better help families manage chronic pain over the long term.\n\nThe project aims to increase knowledge about the effects of psychological treatments - in this case delivered online - for adolescents with chronic pain. As previous studies have highlighted the promise of exposure-based strategies and digital accessibility, the study aims to evaluate the effect of a treatment that combines and optimizes both. The study also aims to better understand the specific impact of pain education as a stand-alone intervention, as this is a growing research field with limited studies in youth. Regarding the parent support component of ACT, the study will evaluate whether changes in parental behaviors related to their child's pain are associated with reduced parenting stress and improved functioning and quality of life in the adolescents. In addition to evaluating treatment outcomes, the study aims to explore the underlying processes that may contribute to the effects of ACT and pain education.",[26,27,204,205,206],"Pain Management","Acceptance and Commitment Therapy","Cognitive Behavior Therapy",[208,209,26,27,204,205,206,210,211,212,213,214],"Pain Science Education","Pain Education","Adolescent","Parent-Child Relations","Psychological Flexibility","iCBT","Telemedicine","2025-05-13",{"date":217,"type":38},"2025-05-20",{"date":219,"type":21},"2025-05",{"date":221,"type":21},"2027-12",{"name":223,"class":136},"Region Stockholm",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":235,"conditions":236,"keywords":245,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100590434","multimodal-imaging-and-biospecimen-collection-for-low-back-pain-lbpb-100590434","NCT06967363","Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)","Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Brain Function in Low Back Pain Patients: a Longitudinal Cohort Study","LBPB","Inclusion Criteria:\n\n1. Adults aged 18 to 80 years.\n2. Diagnosis of low back pain, defined as pain located between the lower costal margins and the gluteal folds, with or without leg pain.\n3. Eligible for surgical or non-surgical treatments.\n4. Willingness to undergo neuroimaging (fMRI), microbiota sampling, psychological assessments, and other related study procedures. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe neurological deficits requiring emergency surgery.\n2. Antibiotic or probiotic use within the past 4 weeks. Suffering from digestive diseases such as irritable bowel syndrome, gastric ulcer, duodenal ulcer, etc.;\n3. Diagnosed spinal infections, tumors, fractures, or inflammatory diseases (e.g., ankylosing spondylitis).\n4. Known severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) that would interfere with study participation.Head trauma; history of substance abuse.\n5. Contraindications to MRI scanning (e.g., pacemaker, metallic implants, severe claustrophobia).\n6. Pregnant or breastfeeding women.\n7. Participation in another interventional clinical trial within the past 3 months.\n8. Working at night shifts or travelling across time zones in the past 6 months.\n9. Excessive consumption of coffee, tea.","85 Years",{"count":234,"type":21},360,"This prospective cohort study investigates the neurobiological, genetic, and psychosocial mechanisms underlying acute and chronic low back pain (LBP). Core objectives include establishing a high-quality biobank to support future research in connectomics, genomics, and biomarker discovery, and identifying predictors of pain progression and treatment response.\n\nThe study will also assess the impact of comorbid conditions such as anxiety, depression, and sleep disturbances on pain perception and clinical outcomes. Longitudinal analyses will explore the dynamic interplay between emotion, cognition, sleep, and pain to inform precision, mechanism-based interventions.\n\nFunctional imaging will be used to examine brain responses to nociceptive modulation, aiming to identify neural circuits involved in pain chronification. By integrating multimodal data-including neuroimaging, neurophysiology, microbiota profiling, polysomnography, and molecular assays-the study will define LBP subtypes, with a particular focus on nociceptive, neuropathic, and nociplastic mechanisms. The ultimate goal is to establish prognostic biomarkers and advance personalized strategies for LBP prevention and treatment.",[237,238,239,26,240,241,242,243,27,61,244],"Chronic Low Back Pain (CLBP)","Acute Low Back Pain","Low Back Pain","Acute Pain","Mental Disorders","Sleep Disorder","Fibromyalgia (FM)","Nonspecific Low Back Pain",[246,247,248,249,177,250],"chronic low pack pain","fMRI","brain function","microbiota","treatment","2025-05-02",{"date":215,"type":38},{"date":254,"type":21},"2025-05-15",{"date":256,"type":21},"2028-12-31",{"name":258,"class":45},"Peking University Third Hospital",2,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":270,"studyType":22,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":77},"100498301","different-treatments-in-chronic-pain-patients-100498301","NCT05768477","Different Treatments in Chronic Pain Patients.","Research of the Different Treatments for Chronic Pain Patients, Their Effectiveness and Associated Predictors, Offered at the Pain Center AZ Sint-Lucas Ghent.","EC_PC_AZSTL","Inclusion Criteria:\n\n* Adults\n* Chronic pain patients\n* Dutch speaking, or good understanding\n\nExclusion Criteria:\n\n* Adults unable to give consent\n* Adults who do not understand Dutch",{"count":269,"type":21},1000,"18 Months","The goal of this observational study is to compare different treatment options in a chronic pain population. The main questions it aims to answer are:\n\n* What is the effectiveness of the different therapy options in the pain center of Sint-Lucas on outcomes related to pain and disability?\n* What are predictive factors for the different therapy options in the pain center of Sint-Lucas? Which factors predict improvement in pain related outcomes?\n\nParticipant data will be gathered as part of their routine care. They can be advised to 4 different treatment options:\n\n* Consultations with the pain specialist\n* Interventions by the pain specialist (infiltrations, denervations)\n* Baxter therapy\n* Interdisciplinary treatment\n\nResearchers will compare patients with different dominant pain mechanisms to see which treatment are most effective for which dominant pain mechanisms.",[26,27],"2024-06-05",{"date":275,"type":38},"2024-06-06",{"date":277,"type":38},"2023-04-06",{"date":133,"type":21},{"name":280,"class":45},"University Ghent"]